dopamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics 947 51-61-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dopamine
  • oxytyramine
  • dopamin
  • dophamine
  • hydroxytyramin
  • dopamine hydrochloride
  • dopamine HCl
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
  • Molecular weight: 153.18
  • Formula: C8H11NO2
  • CLOGP: 0.17
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 3
  • TPSA: 66.48
  • ALOGS: -1.31
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 470 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 100 %
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.74 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 65.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.87 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.42 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 18.96 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.598 Moderate 0.69
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.439 Moderate 0.69
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.531 10^-6 cm/s Moderate 0.69
dh-clint Dog hepatocyte intrinsic clearance 28.445 uL/min/10^6 cells Moderate 0.69
dppb Dog plasma protein binding (% unbound) 83.370 % Moderate 0.69
fcs-ppb Fetal calf serum protein binding (% unbound) 33.230 % Moderate 0.69
herg hERG pIC50 4.143 pIC50 Moderate 0.69
hh-clint Human hepatocyte intrinsic clearance 11.749 uL/min/10^6 cells Moderate 0.69
hlm-clint Human liver microsomal intrinsic clearance 4.227 uL/min/mg protein Moderate 0.69
hppb Human plasma protein binding (% unbound) 78.950 % Moderate 0.69
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK16,CDK19,CDK2,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT1,FLT3,FLT4,GRK2,GRK3,GSK3B,IGF1R,IKBKB,INSR,IRAK1,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK1,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,PTK2,SGK1,SIK2,SIK3,SRC,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 102
kinase-selectivity-class AXL,BRAF,CAMK2B,CAMK2D,DDR1,EIF2AK3,EPHB4,GRK2,INSR,MAP2K6,MAPK12,MAPK8,MARK4,PRKCD,SIK2,STK33,SYK,TEK,TTK,ULK1,ULK2 21
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.105 Moderate 0.69
mh-clint Mouse hepatocyte intrinsic clearance 104.954 Moderate 0.69
mppb Mouse plasma protein binding (% unbound) 72.910 Moderate 0.69
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.489 Moderate 0.69
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 70.290 % Moderate 0.69
rh-clint Rat hepatocyte intrinsic clearance 23.227 uL/min/10^6 cells Moderate 0.69
rh-fuinc Rat hepatocyte fraction unbound in incubation 83.490 % Moderate 0.69
rppb Rat plasma protein binding (% unbound) 71.760 % Moderate 0.69
solubility-dd Solubility at pH 7.4 in DMSO 563.638 uM Moderate 0.69

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 1974 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 128.20 27.27 255 4852 1384043 89239297
Multiple organ dysfunction syndrome 117.27 27.27 63 5044 68273 90555067
Cardiac arrest 85.23 27.27 60 5047 104875 90518465
Hypotension 76.89 27.27 93 5014 325304 90298036
Renal ischaemia 74.92 27.27 15 5092 651 90622689
PCO2 increased 64.77 27.27 15 5092 1298 90622042
Cardiogenic shock 63.86 27.27 30 5077 24438 90598902
Shock 62.17 27.27 31 5076 28747 90594593
Bradycardia 61.31 27.27 45 5062 83802 90539538
Blood bicarbonate decreased 60.93 27.27 17 5090 3102 90620238
Renal failure 57.09 27.27 52 5055 130955 90492385
Hypertrophic cardiomyopathy 56.89 27.27 15 5092 2213 90621127
Left ventricle outflow tract obstruction 56.28 27.27 11 5096 421 90622919
Pulmonary oedema 56.26 27.27 38 5069 62042 90561298
Diabetes insipidus 55.92 27.27 16 5091 3196 90620144
Blood pH decreased 54.84 27.27 15 5092 2543 90620797
PO2 increased 53.77 27.27 12 5095 880 90622460
Status epilepticus 51.91 27.27 24 5083 18850 90604490
Oxygen saturation abnormal 51.35 27.27 16 5091 4272 90619068
Renal impairment 50.19 27.27 44 5063 105377 90517963
Intentional overdose 48.39 27.27 41 5066 93793 90529547
Ventricular tachycardia 45.77 27.27 24 5083 24684 90598656
Renal injury 44.53 27.27 18 5089 10225 90613115
Drug ineffective for unapproved indication 42.56 27.27 33 5074 66611 90556729
Seizure 39.87 27.27 46 5061 152583 90470757
Electroencephalogram abnormal 39.65 27.27 13 5094 4083 90619257
Blood pressure decreased 39.17 27.27 33 5074 74862 90548478
Enzyme induction 38.70 27.27 6 5101 56 90623284
Disseminated intravascular coagulation 37.29 27.27 20 5087 21518 90601822
Acute kidney injury 36.54 27.27 65 5042 320322 90303018
Metabolic acidosis 36.49 27.27 28 5079 55648 90567692
Electrocardiogram QRS complex prolonged 35.72 27.27 14 5093 7334 90616006
Cardiopulmonary failure 35.40 27.27 12 5095 4176 90619164
Clonus 35.34 27.27 13 5094 5737 90617603
Foetal death 35.20 27.27 19 5088 20704 90602636
Circulatory collapse 34.57 27.27 20 5087 24884 90598456
Blood magnesium decreased 34.16 27.27 17 5090 15676 90607664
Left ventricular dysfunction 32.26 27.27 16 5091 14653 90608687
Stress cardiomyopathy 30.66 27.27 15 5092 13340 90610000
Cardiac assistance device user 30.52 27.27 5 5102 68 90623272
Myocardial ischaemia 30.18 27.27 15 5092 13799 90609541
Toxicity to various agents 29.77 27.27 56 5051 287790 90335550
Respiratory failure 29.76 27.27 35 5072 118383 90504957
Sepsis 29.39 27.27 43 5064 179771 90443569
Newborn persistent pulmonary hypertension 29.29 27.27 6 5101 292 90623048
Platelet count decreased 28.79 27.27 37 5070 136932 90486408

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 121.65 23.41 234 4491 629963 41986647
Multiple organ dysfunction syndrome 68.49 23.41 68 4657 96967 42519643
Hypotension 58.27 23.41 103 4622 257528 42359082
Disseminated intravascular coagulation 56.91 23.41 35 4690 24759 42591851
Cardiac arrest 51.59 23.41 62 4663 109258 42507352
Metabolic acidosis 43.47 23.41 40 4685 51818 42564792
Cardiogenic shock 41.08 23.41 33 4692 35607 42581003
Acute kidney injury 40.54 23.41 110 4615 367227 42249383
Shock 37.96 23.41 29 4696 29092 42587518
Blood urea increased 37.02 23.41 30 4695 32763 42583847
Torsade de pointes 35.88 23.41 18 4707 8576 42608034
Ventricular fibrillation 32.83 23.41 27 4698 30096 42586514
Drug ineffective for unapproved indication 30.03 23.41 31 4694 46132 42570478
Acidosis 29.87 23.41 18 4707 12261 42604349
Renal failure 28.00 23.41 54 4671 143672 42472938
Cardiac failure 27.02 23.41 45 4680 106811 42509799
Oliguria 26.20 23.41 15 4710 9298 42607312
Ventricular tachycardia 24.74 23.41 23 4702 30137 42586473
Renal impairment 23.42 23.41 43 4682 110185 42506425

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 198.92 22.34 396 8404 1520144 109060355
Multiple organ dysfunction syndrome 147.90 22.34 111 8689 151599 110428900
Cardiac arrest 124.56 22.34 112 8688 196641 110383858
Hypotension 121.68 22.34 177 8623 523672 110056827
Cardiogenic shock 99.33 22.34 60 8740 57278 110523221
Shock 92.62 22.34 56 8744 53532 110526967
Disseminated intravascular coagulation 89.54 22.34 50 8750 41236 110539263
Acute kidney injury 68.69 22.34 154 8646 635276 109945223
Renal failure 63.54 22.34 84 8716 226490 110354009
Metabolic acidosis 63.45 22.34 57 8743 99687 110480812
Ventricular tachycardia 63.41 22.34 43 8757 49966 110530533
Bradycardia 60.41 22.34 68 8732 155449 110425050
Renal impairment 59.32 22.34 74 8726 188371 110392128
PCO2 increased 58.13 22.34 16 8784 1961 110578538
Blood urea increased 57.47 22.34 42 8758 54915 110525584
Ventricular fibrillation 55.92 22.34 37 8763 41276 110539223
Pulmonary oedema 55.28 22.34 53 8747 100606 110479893
Renal ischaemia 51.14 22.34 15 8785 2308 110578191
Drug ineffective for unapproved indication 50.60 22.34 51 8749 102787 110477712
Left ventricle outflow tract obstruction 49.99 22.34 11 8789 532 110579967
Septic shock 49.79 22.34 62 8738 157466 110423033
Blood pressure decreased 49.32 22.34 53 8747 115038 110465461
Cardiac failure 48.67 22.34 67 8733 187559 110392940
Respiratory failure 48.67 22.34 72 8728 215260 110365239
Blood pH decreased 48.38 22.34 17 8783 4652 110575847
Diabetes insipidus 46.24 22.34 18 8782 6552 110573947
Oxygen saturation abnormal 45.34 22.34 17 8783 5594 110574905
Blood bicarbonate decreased 44.80 22.34 17 8783 5780 110574719
Intentional overdose 43.23 22.34 53 8747 132448 110448051
PO2 increased 43.00 22.34 12 8788 1547 110578952
Sepsis 42.97 22.34 86 8714 327260 110253239
Acidosis 42.70 22.34 25 8775 22506 110557993
Status epilepticus 37.30 22.34 26 8774 31545 110548954
Platelet count decreased 36.99 22.34 66 8734 230377 110350122
Fatigue 36.88 22.34 26 8774 1215932 109364567
Toxic epidermal necrolysis 35.23 22.34 32 8768 56695 110523804
Torsade de pointes 34.91 22.34 22 8778 22578 110557921
Stress cardiomyopathy 33.86 22.34 19 8781 15787 110564712
Seizure 33.78 22.34 62 8738 221123 110359376
Foetal death 33.60 22.34 19 8781 16026 110564473
Enzyme induction 32.43 22.34 6 8794 119 110580380
Headache 32.24 22.34 15 8785 882362 109698137
Arthralgia 32.16 22.34 11 8789 779621 109800878
Acute respiratory distress syndrome 31.07 22.34 29 8771 53169 110527330
Circulatory collapse 30.18 22.34 26 8774 42967 110537532
Electroencephalogram abnormal 30.09 22.34 13 8787 6160 110574339
Hepatic function abnormal 29.57 22.34 36 8764 89259 110491240
Left ventricular dysfunction 29.29 22.34 20 8780 23473 110557026
Neutrophil count increased 28.57 22.34 23 8777 34629 110545870
Lactic acidosis 28.46 22.34 36 8764 92775 110487724
Blood magnesium decreased 27.27 22.34 18 8782 19978 110560521
Incision site pain 27.17 22.34 10 8790 3125 110577374
Myocardial ischaemia 27.00 22.34 20 8780 26664 110553835
Hypernatraemia 26.65 22.34 17 8783 17816 110562683
Renal injury 25.90 22.34 17 8783 18696 110561803
Clonus 25.80 22.34 13 8787 8703 110571796
Cardiac assistance device user 25.69 22.34 5 8795 131 110580368
Lymphocyte count decreased 25.63 22.34 27 8773 57216 110523283
BRASH syndrome 25.49 22.34 10 8790 3713 110576786
Obstructive shock 25.14 22.34 5 8795 147 110580352
Hepatic failure 24.88 22.34 29 8771 68710 110511789
Weight decreased 24.38 22.34 4 8796 468053 110112446
Systolic dysfunction 23.84 22.34 10 8790 4405 110576094
Oliguria 23.54 22.34 16 8784 18641 110561858
Sinus bradycardia 23.10 22.34 19 8781 29464 110551035
Haemodynamic instability 22.81 22.34 17 8783 22871 110557628
Urine output decreased 22.62 22.34 16 8784 19860 110560639
Rhabdomyolysis 22.62 22.34 37 8763 120364 110460135
N-terminal prohormone brain natriuretic peptide 22.37 22.34 4 8796 65 110580434

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA04 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA CS M0003647 Catecholamines
FDA EPC N0000175570 Catecholamine
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35522 ฮฒ-adrenergic agonist
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:38147 cardiotonic drug
CHEBI has role CHEBI:48560 dopaminergic agent
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77746 human metabolite

Related Drugs by ATC class:

C01CA Adrenergic and dopaminergic agents 25 drugs
amezinium metilsulfatearbutaminecafedrinedimetofrinedobutaminedopexaminedroxidopaephedrineepinephrineetilefrinefenoldopamgepefrine show all 25 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Low cardiac output syndrome indication 44088000
Low blood pressure indication 45007003
Decompensated cardiac failure indication 195111005
Sinus bradycardia off-label use 49710005
Acute nephropathy off-label use 58574008
Tachyarrhythmia contraindication 6285003
Hypovolemia contraindication 28560003
Ventricular arrhythmia contraindication 44103008
Acidosis contraindication 51387008
Pheochromocytoma contraindication 302835009
Hypoxia contraindication 389086002
Occlusive Vascular Disease contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.96 acidic
pKa2 12.98 acidic
pKa3 10.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR AGONIST Ki 5 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Kd 4.19 CHEMBL
D(1A) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
D(2) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter IC50 8.18 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 5.08 PDSP
D(3) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
D(1B) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.19 CHEMBL
D(4) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Trace amine-associated receptor 1 GPCR Ki 6.38 WOMBAT-PK
Melatonin receptor type 1A GPCR Ki 5.15 CHEMBL
Melatonin receptor type 1B GPCR Ki 5.04 CHEMBL
Lysine-specific demethylase 4E Enzyme IC50 5.52 CHEMBL
Dopamine beta-hydroxylase Enzyme Km 3 WOMBAT-PK
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.85 CHEMBL
Alpha-synuclein Transporter IC50 6.28 CHEMBL
D(2) dopamine receptor GPCR Ki 8.35 CHEMBL
Sodium-dependent dopamine transporter Transporter IC50 6.70 CHEMBL
D(1A) dopamine receptor GPCR Ki 8.15 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.82 CHEMBL
D(2) dopamine receptor GPCR Ki 8.74 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 4.30 CHEMBL
D(3) dopamine receptor GPCR Ki 7.96 CHEMBL
D(4) dopamine receptor GPCR EC50 8.62 CHEMBL
Opioid receptor GPCR IC50 5.52 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.24 CHEMBL
Dopamine receptor GPCR IC50 8.43 CHEMBL
Dopamine receptor GPCR IC50 5.27 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 4.85 CHEMBL
Adenylate cyclase Enzyme EC50 5.46 CHEMBL
Adenosine A2b receptor GPCR Ki 6.01 CHEMBL
M18 aspartyl aminopeptidase Enzyme IC50 5.70 CHEMBL

External reference:

IDSource
4019733 VUID
N0000147825 NUI
D00633 KEGG_DRUG
62-31-7 SECONDARY_CAS_RN
4018656 VANDF
4019733 VANDF
C0013030 UMLSCUI
CHEBI:18243 CHEBI
LDP PDB_CHEM_ID
CHEMBL59 ChEMBL_ID
DB00988 DRUGBANK_ID
CHEMBL1557 ChEMBL_ID
D004298 MESH_DESCRIPTOR_UI
681 PUBCHEM_CID
2417 INN_ID
940 IUPHAR_LIGAND_ID
VTD58H1Z2X UNII
3628 RXNORM
3090 MMSL
4632 MMSL
6641 MMSL
d00216 MMSL
001787 NDDF
004721 NDDF
16257000 SNOMEDCT_US
412383006 SNOMEDCT_US
59187003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9252 INJECTION 40 mg INTRAVENOUS ANDA 15 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9253 INJECTION 80 mg INTRAVENOUS ANDA 15 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9254 INJECTION 40 mg INTRAVENOUS ANDA 15 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9255 INJECTION 80 mg INTRAVENOUS ANDA 15 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1005 INJECTION, SOLUTION 80 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1007 INJECTION, SOLUTION 160 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1009 INJECTION, SOLUTION 320 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9981 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 15 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9981 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 15 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9982 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 15 sections
Dopamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-0042 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 25 sections
Dopamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-1858 INJECTION, SOLUTION 3.20 mg INTRAVENOUS NDA 25 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-5820 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 24 sections
Dopamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-7809 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 25 sections
Dopamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-7810 INJECTION, SOLUTION 3.20 mg INTRAVENOUS NDA 25 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-9104 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 24 sections
DOPAMINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1220 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 12 sections
DOPAMINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1291 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 12 sections
DOPAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1316 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 13 sections
DOPAMINE HCI IN 5% DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1458 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 13 sections
DOPAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1489 INJECTION 40 mg INTRAVENOUS ANDA 11 sections
DOPAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1490 INJECTION 40 mg INTRAVENOUS ANDA 11 sections
dopamine hydrochloride in dextrose HUMAN PRESCRIPTION DRUG LABEL 1 51662-1681 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 16 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71872-7066 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 17 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71872-7305 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 84549-007 INJECTION, SOLUTION 160 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 84549-252 INJECTION 40 mg INTRAVENOUS ANDA 15 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 84549-820 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 24 sections